Sermorelin

Definition

Sermorelin is the first 29 amino acids of growth hormone-releasing hormone, the shortest fragment that retains the full hormone's activity at the pituitary; it stimulates the body's own growth hormone release rather than replacing the hormone directly.

Its regulatory history distinguishes it from most compounded peptides: sermorelin was an approved drug, marketed as Geref for pediatric growth hormone deficiency, and it was discontinued in 2008 for commercial rather than safety reasons, with FDA withdrawing the approval the following year.

Evidence

The approval-era evidence is pediatric: in a one-year study of once-daily subcutaneous GHRH(1–29) in prepubertal children with growth hormone deficiency, treatment accelerated growth velocity ^[1]. Adult use for body composition, sleep, or longevity rests on the pharmacology rather than on comparable trials; a 2026 review of GH-axis peptides finds the clinical evidence for such uses thin ^[2].

A reader weighing sermorelin against injected growth hormone is weighing a stimulus with intact feedback control against direct replacement; the safety argument favors the former, and the outcome data for modern adult indications are limited for both.

Counted across the names the compound is indexed under, the record is 562 papers, of which 71 carry the clinical-trial publication type and 39 the stricter randomized-controlled-trial type; 52 of the 71 carry the adult subject heading and 19 the child heading ^[6]. The distribution by publication year is itself a finding: 9 of the 71 appeared before 1990, 57 during the 1990s, 5 between 2000 and 2009, and none since, the most recent having been published in 2005 ^[6].

Three of those trials are indexed under body composition, all three were read, and they do not agree. A 16-week single-blind randomized placebo-controlled study in 19 adults aged 55 to 71 found that nocturnal growth hormone and serum IGF-1 rose, that lean body mass increased in the men only, and that no other measure of body composition or bone mineral density changed in either sex; sleep quality was unaffected ^[3]. A 6-week study in 11 men aged 64 to 76 found that nightly injection raised nocturnal growth hormone release with no change in IGF-1, IGF binding protein 3, or the dual-energy x-ray absorptiometry measures of muscle and fat ^[4]. A 14-day dose-comparison study in 10 men of mean age 68 raised 24-hour growth hormone and IGF-1 to the levels measured in young men, but only at the higher of the two doses, and it measured hormones rather than body composition ^[5].

Side effects

The published trials report few adverse effects, but they are small and old. In the one-year pediatric study behind the Geref approval, treatment was well tolerated, with no adverse changes in blood chemistry or hormone measures and no excess rise in IGF-1 ^[1]. In the placebo-controlled study of 19 adults aged 55 to 71, the only adverse effect reported was a transient rise in blood lipids that resolved by the end of the study ^[3], and the six-week study in older men observed no significant adverse effects ^[4].

None of those trials was designed or sized to detect uncommon harms, and none tested the compounded products sold today for adult wellness uses. Because sermorelin works by stimulating the body's own growth hormone release, the long-term questions are those of raising growth hormone and IGF-1 over years, which the trial record, the most recent of it published in 2005, does not answer ^[6].

Educational summary of the cited sources, not medical advice; a prescriber weighs these risks against a person’s own history.

Lawful access

Licensed 503A pharmacies compound sermorelin with a valid prescription; its history as a component of an approved drug is what makes that position durable.

Material sold without a prescription as research-use-only sermorelin sits outside pharmacy quality standards, whatever the molecule's own status.

The withdrawal record is public and dated. Geref was the subject of two applications, one approved December 28, 1990 and one approved September 26, 1997; the sponsor notified the FDA by letter of December 2, 2008 that the product was being discontinued and asked that the application be withdrawn, the agency published the withdrawal of approval on May 19, 2009 effective June 18, 2009, and in a determination published March 4, 2013 the agency found that the Geref presentations were not withdrawn from sale for reasons of safety or effectiveness ^[7]. That last finding is the one that matters to a reader: the product left the market on a commercial decision, and the agency said so in a document written for the purpose.

Drugs@FDA lists the first application, NDA 019863, as a new molecular entity and the second, NDA 020443, as a new dosage form with orphan status; both are marked discontinued with a note recording that Federal Register determination, and no Geref label is available on the site ^{[8, 9]}.

Related molecules

Sermorelin anchors the GH secretagogues class beside tesamorelin, the class's approved drug, and CJC-1295, a long-acting analogue with no lawful route; the compoundable status page lists what a 503A pharmacy may prepare today. Two further members of the class, GHRP-2 and GHRP-6, hold a third position again: Category 3 of the 503A list, which records that a nomination was too thin to evaluate rather than anything about the substance. Sermorelin vs tesamorelin sets the two GHRH analogs side by side on structure, evidence and legal access.

Elsewhere in this index